Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
In 2016, Amgen’s (AMGN) Neulasta generated revenues close to $4.6 billion, which was a slight drop from its 2015 net sales of ~$4.7 billion.
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
Mylan’s Key Developments and Big Plans: What You Should Know
The recent developments reported by Mylan (MYL) include commercial developments and product developments. Let’s take a closer look.
Mylan (MYL) reported an increase of 17% in revenues at ~$2.2 billion in 1Q16 from $1.9 billion in 1Q15.
The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.
Medicare Business Expected to Drive WellCare Health Plans’ Margin Growth
In 1Q17, WellCare Health Plans’ (WCG) Medicare Health Plans business reported revenues close to $1.1 billion, which represents year-over-year growth of ~12.4%.
WellCare Health Plans has updated its earnings per share guidance from the previously estimated range of $6.00–$6.25 to the new range of $6.55–$6.80.
In 1Q17, WellCare Health Plans (WCG) reported revenues of ~$3.9 billion, which totals year-over-year growth of around 11.7%.
Molina Healthcare: Why Molina’s revenues have been growing fast
Molina Healthcare, Inc. (MOH): Revenue growth In general, Medicaid health plans grow revenue by increasing their membership or generating higher rates from state governments. The latter portion is often left up…
Investor day could provide a positive update to long-term growth MOH has been under pressure of late, without much reason. After beating 2Q consensus EPS estimates, even after including roughly…
Molina Healthcare, Inc. (MOH): Market overview Medicaid is a rapidly growing segment within healthcare, which should directly benefit MOH. In addition to typical market growth of mid-single digits, there are several…
Yellen’s Caution Led Battered Healthcare Up 1.2% on March 29
With the Fed stressing caution, investor sentiment turned toward the utilities and healthcare sectors, which rose 1.5% and 1.2%, respectively, on March 29.
Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.
The Health Care Select Sector SPDR ETF (XLV) has by and large been an outperformer in 2015. It has returned 5.1% on a YTD (year-to-date) basis.
How Could Trump’s Presidency Affect Hospitals and Insurance?
Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it with another policy, the hospital…
While the recent trade cases have buoyed the US steel industry, Europe is still weak. A major recovery in U.S. Steel’s Europe earnings looks elusive in the near-term.
Wall Street analysts have projected that Universal Health Services’ net profit margin will increase marginally from 7.5% in 2015 to 7.6% in 2016.
A Look at Medtronic’s Recent Stock Performance
Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.
In a Reuters survey of 25 brokerage companies on May 22, 2017, ~56% of analysts rated Medtronic as a “buy,” and 44% rated it as a “hold.”
Medtronic accounts for ~1.1% of the total holdings of the iShares Russell 1000 Value ETF. The company has consistently reported higher earnings than analysts’ earnings estimates.
Performance of Merck’s Animal Health Segment in 1Q17
Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales in 1Q17 were $939.0 million, a 13.0% rise from 1Q16.
Remicade, a top-selling drugs for the treatment of inflammatory disorders, is losing market share after the loss of exclusivity in European markets in February 2015.
Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.